+ New Watchlist

Benzinga Research

Get Benzinga Pro
Data & APIs
Events
Marketfy
Premarket
Boost
Advertise

Our Services
News
Earnings
Guidance
Dividends
M&A
Buybacks
Legal
Interviews
Management
Offerings
IPOs
Insider Trades
Biotech/FDA
Politics
Healthcare
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Binary Options
Bonds
Futures
CME Group
Global Economics
Mining
Previews
Small-Cap
Real Estate
Penny Stocks
Digital Securities
Volatility
Options
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Whisper Index
Stock of the Day
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Prop Trading
Credit Cards
Stock Brokers
Crypto
Cannabis
Cannabis Conference
Earnings
Interviews
Deals
Regulations
Psychedelics

Free Benzinga Pro Trial

Calendars

Analyst Ratings Calendar

Conference Call Calendar

Dividend Calendar

Earnings Calendar

Economic Calendar

Guidance Calendar

Stock Split Calendar

Trade Ideas

Free Stock Reports

Trade Idea Feed

Analyst Ratings

Unusual Options Activity

Free Newsletter

Government Trades

Perfect Stock Portfolio

Easy Income Portfolio

Short Interest

Largest Increase

Largest Decrease

Calculators

Margin Calculator

Forex Profit Calculator

100x Options Profit Calculator

Comments

Loading...

Awakn Life Sciences

AWKNFOTCQB

Logo brought to you by Benzinga Data

Perks Buy Compare Brokers

Perks Buy Compare Brokers

$0.091200

0.00384.29%

At close: -

$0.100000

0.00889.65%

After Hours: Oct 15, 9:26 AM EDT

Awakn Life Sciences (AWKNF) Forecast

News

Earnings Awakn Life Sciences (AWKNF) Options Guidance Dividends Analyst Ratings Insider Trades Short Interest

Latest news for Awakn Life Sciences (OTC:AWKNF) Stock

Awakn Life Sciences Stock (OTC: AWKNF)

Categories: All

All News

General

Contracts

Dividends

Events

FDA

M&A

Offerings

Stock Split

Media

Buybacks

Insider Trades

Earnings

Guidance

Analyst Ratings

Trading Ideas

All News

General

Contracts

Dividends

Events

FDA

M&A

Offerings

Stock Split

Media

Buybacks

Insider Trades

Earnings

Guidance

Analyst Ratings

Trading Ideas

Tuesday, October 15, 2024

Awakn Partners With University Of Nottingham For Preclinical Testing Of Psychoactive Therapy
Juan Spínelli

Wednesday, September 18, 2024

Investors Back Awakn's Psychedelic Therapies, As Company Doubles Private Placement To $2M
Juan Spínelli

Wednesday, April 17, 2024

Psychedelics Headlines: Dementia Prevention, Psychological Flexibility, Ancient Romans' Trips And More
Lara Goldstein

Thursday, February 15, 2024

Psychedelics Headlines: Trauma-Informed Care, Valentine's Day & MDMA, Academics On Drugs And More
Lara Goldstein

Friday, January 26, 2024

Psychedelics Headlines: Anti-inflammatory Effects, Global Drug Survey, 'Synthetic Surprise,' UK's Harm Reduction Hub And More
Lara Goldstein

Wednesday, December 27, 2023

Psyched: Biden Approves Psychedelics Trials, RFK, Australia's First Legal Dedicated Clinic & More
Lara Goldstein

Thursday, December 21, 2023

Awakn Life Sciences Enters Into Global Licensing Agreement For Sublingual Delivery Formulation
The Dales Report

Friday, November 24, 2023

Psyched: Ramaswamy Psychedelics For PTSD, UK Clinical Trials, Johns Hopkins Q&A And More
Lara Goldstein

Wednesday, November 15, 2023

UK Psychedelics: Phase 3 Depression & Alcohol Addiction Trials, New London Center
Lara Goldstein

Monday, October 16, 2023

U.K.'s Prof. David Nutt Ranked World's Top Psychopharmacologist: More On His Contributions & Advocacy
Lara Goldstein

Monday, September 11, 2023

Psyched: Psilocybin Therapy For Depression, UK Rescheduling, US Policy Reform And More
Lara Goldstein

Wednesday, September 06, 2023

Awakn Life Sciences Submits CTA For Phase III Alcohol Use Disorder Clinical Trial
The Dales Report

Monday, August 14, 2023

Psyched: Professional Practice Guidelines, DMT For Stroke, Dua Lipa &. Amanda Feilding, Clinical Results & More
Lara Goldstein

Thursday, August 03, 2023

Psyched: Portugal Decriminalizes Synthetic Drugs, Anorexia And Psilocybin, LSD Microdosing, California & More
Lara Goldstein

Tuesday, August 01, 2023

Awakn Life Sciences Becomes Pure R&D Biotech After Sale Of Norway Clinics
Lara Goldstein

Wednesday, July 26, 2023

Awakn Life Sciences On Track With Phase 3 Trial To Research Substance Use Disorder
The Dales Report

Tuesday, July 11, 2023

Psyched: Australia's Innovative Program, Congressional Amendments, Therapy Reimbursement And More
Lara Goldstein

Wednesday, July 05, 2023

Awakn Life Sciences Sells London Clinics Business, Hopes To Divest Norwegian Unit Next
Lara Goldstein

Tuesday, June 20, 2023

Psyched: $75M In Federal Funds, Gov. Polis Opens MAPS Event, CNN's Show, Dock Ellis' LSD Pitch & More
Lara Goldstein

Friday, June 16, 2023

Awakn Life Sciences Announces Closing Of Second Tranche And Upsizing Of Previous Private Placement
Lara Goldstein

Monday, June 12, 2023

Awakn To Focus On R&D Of Addiction Therapies, Moves Away From Ketamine Treatment For Alcoholism
Lara Goldstein

Monday, May 01, 2023

Psyched: Oregon And Colorado Regulations, MindMed CEO Discusses LSD Therapy, Mia Khalifa Enters Market & More
Lara Goldstein

Friday, April 28, 2023

Awakn's Q4 2023 And Annual Financials, +500% YoY Revenue Increase Following Network Expansion
Lara Goldstein

Monday, April 24, 2023

Psyched: LSD For Major Depression, Canada's Psilocybin Macrodose Trial, Treatments For Multiple Sclerosis And More
Lara Goldstein

Wednesday, April 19, 2023

Severe Alcohol Use Disorder Patients Will Try Ketamine Therapy At Awakn's New Phase 3 Study
Lara Goldstein
EXCLUSIVE: MDMA Therapy Experts Debate Upcoming Approval And Psychedelic Market Opps
Lara Goldstein

Monday, April 17, 2023

Psyched: Clinical-Grade MDMA, LSD For Depression, Partnerships For Delivering Psychedelic Therapies & More
Lara Goldstein

Friday, April 14, 2023

Awakn's Psychedelics Medical Chief Steps Down, Shifts In Company's Stocks And Ownership
Lara Goldstein

Sunday, March 19, 2023

EXCLUSIVE: Ketamine Therapy Provider Nushama Co-Founder On Shifting From A Consciousness Of Blame Into A Space Of Responsibility
Lara Goldstein

Monday, March 13, 2023

Major Psychedelics VC & EFT Directors Will Share Valuable Insights At Upcoming Benzinga Event
Lara Goldstein

Tuesday, March 07, 2023

Psyched: 9 US Reform Bills, Ayahuasca 'A Release' For Prince Harry, At-Home Therapy & More
Lara Goldstein

Thursday, March 02, 2023

MDMA News: Exclusive Supply Deal With Awakn Life Sciences & Canadian Company Expands Psychedelics Production
Lara Goldstein
Latest Psychedelics Deals: Optimi Supplies Australia, Awakn Partners Licensing In California
Lara Goldstein

Tuesday, February 28, 2023

Psyched: Hawaii And Minnesota's Bills, Studying 2C-B Vs. Psilocybin, Filament CEO, Plus Brock Pierce And Jeremy Gardner Discuss The Industry's Future And More
Lara Goldstein

Wednesday, February 22, 2023

Awakn's First Licensing Partnership Deal In Europe Involves Chain Of Portuguese Clinics
Lara Goldstein

Tuesday, February 21, 2023

Psyched: Four New States With Reform Bills, Psilocybin For Genetic Disorders And Functional Neurological Disorder, Struggle For Access & More
Lara Goldstein

Tuesday, February 14, 2023

Psychedelics For Alcohol Use Disorder: Awakn Opens European Clinic, FSD Launches R&D Program
Lara Goldstein

Monday, February 13, 2023

Psyched: 12 States Discuss Legalization Bills, Ceremonies For Veterans With TBI, Ketamine And MDMA Fast-Tracks & More
Lara Goldstein

Thursday, February 09, 2023

A New Way Of Delivering MDMA? Awakn And Tech Partner Are Set To Study Viability
Lara Goldstein

Tuesday, February 07, 2023

Awakn's Ketamine Treatment For Alcohol Use Disorder Awarded UK's Fast-Track Status
Lara Goldstein

Tuesday, January 24, 2023

Two New Studies On Classical Psychedelics: Grading Ketamine's Components, Tuning Down Psilocybin Dosing
Lara Goldstein

Wednesday, January 04, 2023

These Are The 11 Biggest Psychedelics News And Trends You May Have Missed Last Year
Lara Goldstein

Tuesday, December 20, 2022

Psyched: First Ayahuasca Pill Created, Psychedelics Legalization Predicted, UK's Research Support And More
Lara Goldstein

Friday, December 16, 2022

Awakn Unveils Q3 Results, Touts Revenue Growth, R&D Progress, Commercial Plans
Lara Goldstein

Tuesday, December 13, 2022

UK Supports Psychedelic Research With Phase 3 Trial In Federal Health Sites
Lara Goldstein

Tuesday, December 06, 2022

Psyched: Fed Guidelines And Research Production Quotas, Protests In Canada, Cal's Decrim Project
Lara Goldstein

Saturday, December 03, 2022

Europe To Have Expanded Access To Psychedelic-Assisted Therapy With New Norway Clinic
Lara Goldstein

Tuesday, November 29, 2022

Psyched: Full-Dose & Microdosing LSD Studies, Research Scope For Fed Funding, Consumption Sites And More
Lara Goldstein

Wednesday, November 23, 2022

A Leading Ketamine Treatment Clinic For Alcoholism Is Expanding: Here's The Latest
Lara Goldstein

Popular Channels

PreMarket Prep
Press Releases
Analyst Ratings
News
Options
ETFs

Tools & Features

Real Time Feed
Public RSS Feeds
Submit News Tips
Blog
Embeddable Finance Widgets & Tools
Benzinga Catalyst

Partners & Contributors

Affiliate Program
Contributor Portal
Licensing & Syndication
Sponsored Content
Advertise With Us
Lead Generation & SEO

About Benzinga

About Us
Careers
In The News
Events
Contact Us

Terms & Conditions
Do Not Sell My Personal Data/Privacy Policy
Disclaimer
Service Status
Sitemap

© 2024 Benzinga | All Rights Reserved